Wolfgang Miesbach/LinkedIn
Dec 7, 2025, 16:21
Wolfgang Miesbach: Beyond Immunosuppression – Two new ways to treat ITP
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
“Beyond Immunosuppression: Two new ways to treat ITP. David Kuter gave a great presentation at ASH 2025:
- Increase Platelet Production
The latest TPO receptor agonist, hetrombopag, now in Phase 3 trials, offers a direct pathway to boost platelet synthesis—moving away from suppression toward restoration. - Decrease Platelet Destruction
A diverse arsenal of targeted therapies can redefineour strategy:
– Anti-CD38 antibodies (daratumumab, mezagitamab)
– BAFF/BAFF-R inhibitors
– FcRn inhibitors (efgartigimod)
– BTK inhibitors (rilzabrutinib, orelabrutinib)
– Complement inhibitors + immunomodulatory approaches
– T-cell engagers and CAR-T therapies
ITP is now recognized as a disorder of both reduced production AND increased destruction—this understanding drives treatment selection toward complete remission, not just disease suppression.”
Find the full coverage of ASH25 in Hemostasis Today.
-
Dec 19, 2025, 06:13Anna Aldehag Reflects on Her 12 Year Leadership in Sweden National Board of Health and Welfare
-
Dec 19, 2025, 05:54Abdul Mannan: APTT Mixing Studies Confuse a Lot of People
-
Dec 18, 2025, 23:14The “Normal” FVIII Level Trap in Females with Haemophilia
-
Dec 18, 2025, 23:11WFH Expands Multidisciplinary Bleeding Disorder Training in Vietnam
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders
-
Dec 18, 2025, 16:50Marie Cambot on Innovhem’s Quantification of The HbF/HbS Ratio for SCD
-
Dec 18, 2025, 16:26Yogesh Rathod on Hematological Issues and ICU
-
Dec 18, 2025, 16:09Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
-
Dec 18, 2025, 15:23Michael Hadley: Well-Timed ACC Statement Just Out in JACC Journals